PRESENTATION
Q2 2022 — Earnings presentation
Q2 2022PDF · 32 pages2.1 MB
Mike Roman Chairman of the Board & Chief Executive Officer Monish Patolawala Executive Vice President, Chief Financial & Transformation Officer Delivering Performance, Driven by Purpose Bruce Jermeland Senior Vice President, Investor Relations ➢ Creating value through spin off of Health Care business ➢ Taking action to efficiently and equitably resolve Combat Arms Earplugs Version 2 litigation related to Aearo Technologies LLC ➢ Delivering in a challenging environment and updating full-year outlook Kevin Rhodes Executive Vice President, Chief Legal Affairs Officer -- 1 of 32 -- 2 2022 Q2 Earnings – July 26, 2022. All rights reserved. Forward looking statement This presentation contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "estimate," "expect," "aim," "project," "intend," "plan," "believe," "will," "should," "could," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19); (3) foreign currency exchange rates and fluctuations in those rates; (4) liabilities related to certain fluorochemicals, including lawsuits concerning various PFAS-related products and chemistries, and claims and governmental regulatory proceedings and inquiries related to PFAS in a variety of jurisdictions; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2021, as updated by the Company's Current Report on Form 8-K dated April 26, 2022, and any subsequent quarterly reports on Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (11) operational execution, including scenarios where the Company generates fewer productivity improvements than estimated; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company’s Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company’s ability to retain talent; potential impacts on the Company’s relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction; and (16) matters relating to the voluntary chapter 11 proceedings of the Company’s subsidiary Aearo Technologies and certain of its affiliates (the “Aearo Entities”), including legal risks related to the chapter 11 proceedings; potential impacts to the Company’s reputation and its relationships with customers, suppliers, employees, regulators and other counterparties and community members; potential impacts to the Company’s liquidity or results of operations, including risks related to the amount that will be necessary to fully and finally resolve all of the Company’s obligations to make payments to resolve such claims under the terms of its funding and indemnification agreement with the Aearo Entities; and the Aearo Entities’ ability to navigate the chapter 11 proceedings to obtain approval and consummation of a plan of reorganization. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments. This presentation refers to certain non-GAAP financial measures. Refer to 3M’s July 26, 2022, press release for descriptions of non-GAAP financial measures such as free cash flow, adjusted free cash flow, free cash flow conversion, adjusted free cash flow conversion, net debt, adjusted EBITDA, and various measures that adjust for the impacts of special items. Refer also to the appendix of this slide deck for descriptions of non-GAAP measures associated with “New 3M” and certain items specific to the Health Care business segment. These non-GAAP measures are not in accordance with, nor are they a substitute for, GAAP measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in those locations. Note on non-GAAP financial measures -- 2 of 32 -- 3 2022 Q2 Earnings – July 26, 2022. All rights reserved. Creating value through spin off of Health Care Taking action to resolve Combat Arms Earplugs litigation Delivering in a challenging environment • “New 3M” (1) will remain a leading global material science innovator serving customers in a wide range of end markets • Health Care will be a leading global diversified health technology company • Each company will be well-capitalized, more agile and focused, and better positioned for long-term success • Aearo Technologies and related entities – subsidiaries of 3M – have initiated chapter 11 proceedings to resolve current and future Combat Arms Earplugs Version 2 litigation • Intended to facilitate an efficient and equitable resolution of litigation • Sales of $8.7 billion with organic sales growth of one percent year-on-year which included a four percentage point headwind from the combined impact of China COVID-related lockdowns and decline in disposable respirator demand • Adjusted earnings per share of $2.48 in midst of continued uncertain macroeconomic and inflationary environment • Updating full-year outlook to reflect U.S. dollar strength and macroeconomic environment: organic growth 1.5-3.5% and adjusted EPS $10.30-$10.80 3M is taking significant actions to benefit stakeholders (1) “New 3M” defined as 3M pro forma for the spin-off of Health Care. -- 3 of 32 -- 44 2022 Q2 Earnings – July 26, 2022. All rights reserved. Capitalizing on global megatrends Accelerating opportunities in growing markets • Expanding demand for innovation in electronics • Increasing focus on safety • Advancing automotive technology/mobility solutions • Expanding opportunities in digitization • Growing interest in home improvement • Greater customer emphasis on sustainability Increasing need for solutions that enhance care delivery and improve patient outcomes • Aging global population with expanding access to care • Growing demand for virtual and in-home care • Focus on reducing rehospitalizations through infection prevention • Healthcare IT system advances and workflow efficiency demands • Better patient care at lower cost • Data, analytics, and technologies for delivery of precision medicine -- 4 of 32 -- 5 2022 Q2 Earnings – July 26, 2022. All rights reserved. Driving long-term value for shareholders • Creates value by launching two industry-leading, well-capitalized, public companies focused on growth, innovation and shareholder returns − New 3M remains a leading global materials science innovator positioned to win in attractive end markets − Health Care will be a leading global diversified health technology company • Enables tailored capital allocation and investments to drive innovation and growth • Enhances strategic flexibility • Offers distinct and compelling investment profiles appealing to different investor bases • Reduces uncertainty by taking action to efficiently and equitably resolve Combat Arms Earplugs litigation -- 5 of 32 -- 6 2022 Q2 Earnings – July 26, 2022. All rights reserved. Creating value through spin off of Health Care business -- 6 of 32 -- 7 2022 Q2 Earnings – July 26, 2022. All rights reserved. New 3M Health Care Transportation & Electronics 35% Consumer 20% Safety & Industrial 45% Medical Solutions 54% Oral Care 17% Health Information Systems 14% Separation and Purification Sciences 11% Food Safety 4% ~$26.8B Sales (2021) Adj. OI % (2021) 21.7% Adj. OI (2021) $5.8B ~$8.6B Sales (2021) OI % (2021) 23.7% OI (2021) $2.0B Unlocking and unleashing innovation and value creation Applying science to improve lives Enabling better, smarter, safer healthcare Includes Food Safety (~$0.4B), expected to be divested by Sept. 1, 2022, that will no longer be part of Health Care -- 7 of 32 -- 8 2022 Q2 Earnings – July 26, 2022. All rights reserved. • Proven operating model powered by leading science and technology, manufacturing, global capabilities, and iconic brands • Unique and differentiated technologies shared across the organization to better deliver world class customer-driven innovation • Continued focus on active portfolio management • Strong balance sheet and free cash flow to continue to invest in growth markets and return capital to shareholders Digitization E-commerce Robotics and Automation Auto/Mobility Electronics Sustainability Wellbeing Safety Home improvement Select Growth Opportunities Accelerating megatrends favor 3M science and innovation -- 8 of 32 -- 9 2022 Q2 Earnings – July 26, 2022. All rights reserved. Talent Innovation Operations • Attract and engage talent with diverse backgrounds, skills, and experience • Empower our people through technology and flexibility • Continue building on a strong culture of customer-inspired innovation • Customer-focused innovation guides investments and R&D • Data-driven insights create opportunities and value • E-commerce and digital marketplace accelerate customer connectivity • Power end-to-end operations through increased digitization • Capitalize on IP-driven manufacturing expertise • Enhance customer service • Streamline operating model 3M core strengths drive innovative customer solutions -- 9 of 32 -- 10 2022 Q2 Earnings – July 26, 2022. All rights reserved. Patient outcomes improving through greater focus on infection prevention, and reducing rehospitalization Hospitals leveraging more healthcare information technology to improve clinical and operational workflows to drive efficiencies Medicines becoming more complex – requiring specialized, tailored solutions Improving patient experiences in oral care through the combination of material science and digital science Enabling better, smarter, safer healthcare -- 10 of 32 -- 11 2022 Q2 Earnings – July 26, 2022. All rights reserved. 2021 Sales ~$8.6.B 2021 EBITDA ~$2.7B 2021 EBITDA Margin ~31% Health Care Core Strengths: • Proven leadership in multiple care pathways • Positioning in attractive end-markets • Innovation mindset driving improved patient outcomes • Collaborative customer relationships • Deep global regulatory expertise • Operational excellence and strong cash flow • Strong sales growth and profitability with significant recurring sales Creating a diversified healthcare technology leader 1 – Includes Food Safety (~$0.4B), expected to be divested by Sept. 1, 2022, that will no longer be part of Health Care 1 -- 11 of 32 -- 12 2022 Q2 Earnings – July 26, 2022. All rights reserved. Well-positioned in growing healthcare markets Selected Key Opportunities Focused on wound healing and reducing preventable complications Medical Solutions Wound care 6-8% growth $20B+ segment ’24E Long history of commercializing award-winning innovations to improve oral health and aesthetics Dental Oral Care 3-5% growth $10B+ segment ’24E Clinical insights to support decision-making, reduce administrative burden, and integrate workflows Healthcare IT Health Information Systems $40B+ segment ’24E 7-14% growth Leading supplier of membranes used in development and manufacturing of medical devices, vaccines, and therapeutics Biopharma Filtration Separation and Purification Sciences 10-15% growth $10B+ segment ’24E -- 12 of 32 -- 13 2022 Q2 Earnings – July 26, 2022. All rights reserved. Health Care transaction summary • Intended to be a tax-free spin off of Health Care into a standalone publicly-traded company • New 3M expected to retain a 19.9% stake in Health Care to be monetized over time Capitalization Additional Details • Subject to final approval by 3M’s Board of Directors, effectiveness of Form 10, receipt of IRS ruling, completion of financing, and other customary closing conditions • Expected close by year-end 2023 • Anticipate no change in 3M’s capital allocation priorities through separation Transaction Summary • Health Care expected to be spun off with net leverage of 3.0x–3.5x adjusted EBITDA and positioned for rapid deleveraging -- 13 of 32 -- 14 2022 Q2 Earnings – July 26, 2022. All rights reserved. Taking action to efficiently and equitably resolve claims -- 14 of 32 -- 15 2022 Q2 Earnings – July 26, 2022. All rights reserved. • 3M acquired Aearo Technologies in 2008 and since then it has operated as a wholly-owned subsidiary • Claims largely relate to previous generation Combat Arms Earplugs manufactured by Aearo Technologies • Approximately 115,000 filed claims, and an additional 120,000 claims on administrative docket, as of June 30, 2022 Actions Taken Benefits to Stakeholders • Aearo Technologies entities have elected to use well-established chapter 11 procedures to resolve all claims determined to be entitled to compensation • 3M has committed $1B to fund a trust, based on the analysis of an experienced estimator of claims in chapter 11 • 3M has also committed an additional $240M to fund projected case related expenses • 3M will provide additional funding if required under the terms of the agreement • Focuses on achieving an efficient and equitable resolution • Reduces uncertainty and increases clarity for all stakeholders • Reduces cost and time of litigating thousands of cases Taking action to efficiently and equitably resolve claims Background -- 15 of 32 -- 16 2022 Q2 Earnings – July 26, 2022. All rights reserved. Creating value through spin off of Health Care business Taking action to efficiently and equitably resolve Combat Arms Earplugs litigation Delivering in a challenging environment, updating full-year outlook Key Takeaways -- 16 of 32 -- 17 2022 Q2 Earnings – July 26, 2022. All rights reserved. Creating value and delivering for customers • Delivered solid Q2 results while focusing on customers and managing supply chain, inflation, geopolitical and COVID dynamics – Overall demand remains strong across most end-markets – Navigating inflationary pressures through disciplined price actions – Significant Q2 challenges in Greater China region due to COVID lockdowns; stronger than expected improvement in June; expect full recovery through the remainder of the year – Strong U.S. dollar resulted in FX sales translation headwind of ~4% year-on-year – Managing impact of Russia/Ukraine conflict • Announced additional investments to resolve matters in Zwijndrecht, restarted manufacturing operations … ramp up progressing as per plan • Updating full-year outlook to reflect U.S. dollar strength and current macroeconomic environment • Confident in our long-term ability to grow above the macro, drive consistent improvement in margins and strong cash flow Q2 2022 Organic growth +1.0% Includes (~4 ppt) headwind from combined impact of China lockdowns and disposable respirator decline Adjusted operating margin 21.0% Adjusted earnings per share $2.48 -- 17 of 32 -- 18 2022 Q2 Earnings – July 26, 2022. All rights reserved. Q2 2022 operating margin and EPS +9.0% Adjusted operating margin Adjusted earnings per share Commentary Q2 2021 23.4% $2.75 Total organic growth/ productivity/other +0.8% +$0.12 Disposable respirator -0.4% -$0.09 • YoY disposable respirator decline in demand China lockdowns -0.7% -$0.11 • Greater China region impact due to COVID lockdowns Brazil social tax -1.0% -$0.12 • Non-repeat of favorable Q2 2021 Brazil Supreme Court social tax ruling Remaining organic growth/ productivity/other +2.9% +$0.44 • Strong pricing, spending discipline and benefits from restructuring actions • Manufacturing headwinds from global supply chain challenges, including geopolitical impacts • Investments in growth, productivity and sustainability Raw material -3.1% -$0.36 • Raw material and logistics cost inflation FX -0.1% -$0.13 • Net of hedge impact Other expense/income NA -$0.02 • Primarily non-operating pension expense offset by lower net interest expense Adjusted tax rate* NA +$0.05 • Q2 2022 adjusted tax rate of 19.8% versus 21.6% in Q2 2021 Shares outstanding NA +$0.07 • Average diluted shares down ~3% Q2 2022 21.0% $2.48 * The effect of income taxes on items that had specific tax rates are reflected within their respective impacts in the table above. -- 18 of 32 -- 19 2022 Q2 Earnings – July 26, 2022. All rights reserved. Q2 2022 cash flow and balance sheet Adjusted free cash flow • Q2: $1.0B, down 41% YoY; YTD: $1.7B, down 45% YoY Adjusted free cash flow conversion • Expect full-year adjusted free cash flow conversion in the range of 90% to 100% • Q2: 68%, down 33 ppts YoY; YTD: 57%, down 35 ppts YoY • Q2 YoY decline due to working capital; cash impact from capitalization of R&D for U.S. tax purposes, as expected Capital expenditures • Q2: $384M, flat YoY; YTD: $808M, up 15% YoY • Continue to expect full-year capex in the range of $1.7B to $2.0B Net debt • Q2: $13.3B, up 4% YoY Cash returned to shareholders • Q2: dividends $848M • Q2: share repurchases suspended due to pending Food Safety separation • YTD: dividends $1.7B; share repurchases $0.8B Adjusted free cash flow $1.0B -41% year-on-year Adjusted free cash flow conversion 68% -33 ppts year-on-year Cash returned to shareholders $0.8B -38% year-on-year -- 19 of 32 -- 20 2022 Q2 Earnings – July 26, 2022. All rights reserved. Safety & Industrial Transportation & Electronics Health Care Consumer Business Group performance -- 20 of 32 -- 21 2022 Q2 Earnings – July 26, 2022. All rights reserved. Business Group performance Q2 2022 Organic growth Adjusted operating margin Commentary Safety & Industrial 0.7% 21.5% • Organic growth led by abrasives, electrical markets, closure and masking systems, roofing granules, automotive aftermarket, and industrial adhesives and tapes; personal safety declined • Disposable respirator sales declined approximately $150M, or 36% organically YoY; reduced segment organic growth by 5.7 ppts • Adjusted operating margins -2.1 ppts YoY; impacted by China lockdowns and manufacturing productivity headwinds; partially offset by strong spending discipline and restructuring benefits Transportation & Electronics 0.5% 21.0% • Organic growth led by advanced materials and commercial solutions; automotive OEM up low-single digits, while transportation safety and electronics declined • Semiconductor supply chain challenges continued to impact global auto builds and electronics end-markets • Operating margins -0.8 ppts YoY; impacted by manufacturing productivity headwinds due to China lockdowns and shutdown of certain operations in Belgium facility; partially offset by strong spending discipline and restructuring benefits Health Care 4.4% 22.7% • Organic growth led by separation and purification sciences, health information systems, medical solutions, and oral care; food safety was flat • Operating margins -2.6 ppts YoY; impacted by manufacturing productivity headwinds and investments; partially offset by sales growth, strong spending discipline, and restructuring benefits • U.S. elective medical procedure and oral care volumes were approximately 90 to 95 percent of pre-COVID levels, up sequentially from Q1 levels Consumer -2.5% 18.5% • Organic sales grew in both stationery and office and home care; home improvement and consumer health and safety both declined due to strong prior year comparisons • Operating margins -2.2 ppts YoY; impacted by manufacturing productivity headwinds, partially offset by strong spending discipline and restructuring benefits -- 21 of 32 -- 22 2022 Q2 Earnings – July 26, 2022. All rights reserved. 2022 outlook -- 22 of 32 -- 23 2022 Q2 Earnings – July 26, 2022. All rights reserved. Updating estimates to reflect FX and macroeconomic environment Macro: • IPI & GDP: ~3%; most end-markets remain strong • Monitoring Greater China region COVID-related lockdowns • Geopolitical uncertainty due to Russia/Ukraine conflict End-markets/supply chain/inflationary impacts: • Auto OEM builds up ~5% YoY; semiconductor and supply chain challenges along with geopolitical impacts constraining pace of build rate • U.S. healthcare elective procedure volumes ~95% to 100%; U.S. oral care volumes at ~90% by year-end, impacted by COVID-related staff shortages and patient cancellations • Weakening consumer electronics demand, particularly smartphones, tablets and TVs • Monitoring consumer sentiment and spending trends • Expecting supply chain challenges to persist for foreseeable future • Navigating inflationary pressures through disciplined price actions; expect raw material & logistics full-year headwind of $750M to $850M YoY Note: Above guidance does not include the impact of pending separation of Food Safety business via Reverse Morris Trust (RMT) transaction with Neogen Organic sales growth 1.5% to 3.5% Adjusted earnings per share $10.30 to $10.80 Adjusted free cash flow conversion 90% to 100% Updating full-year expectations: 1 FX impact on total sales growth: • -4% vs. -1% previously • U.S. dollar at a 20-year high 2 Organic sales growth: • 1.5% to 3.5% vs. 2% to 5% previously • Ongoing macroeconomic uncertainty -- 23 of 32 -- 24 2022 Q2 Earnings – July 26, 2022. All rights reserved. Q&A Mike Roman Chairman of the Board & Chief Executive Officer Monish Patolawala Executive Vice President, Chief Financial & Transformation Officer Kevin Rhodes Executive Vice President, Chief Legal Affairs Officer Bruce Jermeland Senior Vice President, Investor Relations -- 24 of 32 -- 25 2022 Q2 Earnings – July 26, 2022. All rights reserved. Appendix -- 25 of 32 -- 26 2022 Q2 Earnings – July 26, 2022. All rights reserved. Q2 2022 P&L ($M) Q2 2022 Q2 2021 Change Sales $8,702 $8,950 -2.8% Gross profit $3,609 $4,231 -14.7% % to sales 41.5% 47.3% -5.8 pts SG&A $3,023 $1,746 +73.2% % to sales 34.7% 19.6% +15.1 pts R&D & related $476 $514 -7.4% % to sales 5.5% 5.7% -0.2 pts Operating income $110 $1,971 -94.4% % to sales 1.3% 22.0% -20.7 pts Net income $78 $1,524 -94.9% GAAP earnings per share $0.14 $2.59 -94.7% -- 26 of 32 -- 27 2022 Q2 Earnings – July 26, 2022. All rights reserved. Q2 2022 sales recap Americas EMEA APAC Worldwide Organic growth +3.9% -2.0% -1.8% +1.0% Acquisitions/divestitures —% —% —% —% FX -0.2% -10.2% -6.0% -3.8% Total growth +3.7% -12.2% -7.8% -2.8% U.S. Canada Mexico Brazil China/HK Japan Organic growth +2% +17% +13% +9% -8% +1% -- 27 of 32 -- 28 2022 Q2 Earnings – July 26, 2022. All rights reserved. Business segment information *"Safety & Industrial", "Corporate & Unallocated", "Total Operating Business Segment" and "Total" provided on an adjusted basis Organic growth = organic volume + price ($M) Net Sales Q2 2022 Sales Growth Adjusted Operating Income* Adjusted Operating Margin* Business groups Q2 2022 Q2 2021 Organic growth FX M&A Total Sales Change Q2 2022 Q2 2021 Percent change Q2 2022 Q2 2021 Safety & Industrial $2,924 $3,029 0.7% -4.1% —% -3.4% $630 $714 -11.8% 21.5% 23.6% Transportation & Electronics $2,268 $2,355 0.5% -4.2% —% -3.7% $476 $513 -7.5% 21.0% 21.8% Health Care $2,179 $2,165 4.4% -3.8% —% 0.6% $494 $548 -9.9% 22.7% 25.3% Consumer $1,330 $1,400 -2.5% -2.5% —% -5.0% $247 $290 -14.9% 18.5% 20.7% Total Operating Business Segment $1,847 $2,065 Corporate & Unallocated $1 $1 $(21) $33 Total $8,702 $8,950 1.0% -3.8% —% -2.8% $1,826 $2,098 -13.0% 21.0% 23.4% -- 28 of 32 -- 29 2022 Q2 Earnings – July 26, 2022. All rights reserved. Additional sales detail ($M) Net Sales Business groups Q2 2022 Q2 2021 Abrasives 346 326 Automotive Aftermarket 289 294 Closure and Masking Systems 270 254 Electrical Materials 336 313 Industrial Adhesives & Tapes 586 599 Personal Safety 972 1,125 Roofing Granules 125 121 Other Safety & Industrial — (3) Total Safety & Industrial Business Group 2,924 3,029 Advanced Materials 307 302 Automotive & Aerospace 428 443 Commercial Solutions 448 441 Electronics 863 913 Transportation Safety 222 257 Other Transportation & Electronics — (1) Total Transportation & Electronics Business Group 2,268 2,355 ($M) Net Sales Business groups Q2 2022 Q2 2021 Food Safety 89 94 Health Information Systems 309 299 Medical Solutions 1,169 1,166 Oral Care 357 363 Separation & Purification Sciences 255 247 Other Health Care — (4) Total Health Care Business Group 2,179 2,165 Consumer Health & Safety 145 157 Home Care 261 268 Home Improvement 582 645 Stationery & Office 342 332 Other Consumer — (2) Total Consumer Business Group 1,330 1,400 Corporate & Unallocated 1 1 Total 3M 8,702 8,950 -- 29 of 32 -- 30 2022 Q2 Earnings – July 26, 2022. All rights reserved. Certain non-GAAP measures [A] [B] New 3M (non-GAAP measures)a Year ended December 31, 2021 (dollars in millions) 3M Company Health Care Amount [A-B] % of sales Net sales Safety & Industrial $ 11,981 $ — $ 11,981 45% Transportation & Electronics 9,262 — 9,262 35% Consumer 5,513 — 5,513 20% Health Care 8,597 8,597 — Corporate and Unallocated 2 — 2 Total net sales $ 35,355 $ 8,597 $ 26,758 100% Business segment operating income (measure of segment operating performance) $ 7,369 $ 2,037 $ 5,332 Operating income margin 23.7 % Adjustments for special items: net costs for significant litigation $ 463 N/A $ 463 Adjusted operating income (non-GAAP measure) $ 5,795 Adjusted operating income margin (non-GAAP measure) 21.7% Depreciation and amortization expense $ 636 Business segment EBITDA (non-GAAP measure)b $ 2,673 Business segment EBITDA margin (non-GAAP measure)b 31.1 % Refer also to 3M’s July 26, 2022 press release for descriptions of other non-GAAP financial measures and reconciliations to their most directly comparable GAAP financial measures. (a) Certain amounts – New 3M (net sales, adjusted operating income, adjusted operating income margin, and percentages of business segment net sales) are non-GAAP measures, are not defined under U.S. GAAP and, therefore, should not be considered a substitute for other measures prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. 3M defines these items as the respective consolidated 3M Company amounts minus those of (or calculated without) its Health Care business segment. 3M has announced it will spin off the Health Care business. Amounts described as “adjusted” are adjusted for the impacts of special items. Special items for the periods presented include the items described in the section entitled “Description of Special Items”. The Company believes that Certain amounts – New 3M information is meaningful to investors as they consider how the spin off of the Health Care business may impact 3M’s operating results. (b) Business segment EBITDA and EBITDA margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for other measures prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. For business segments, the Company defines EBITDA as business segment operating income (3M’s measure of segment operating performance) adjusted for depreciation and amortization expense. The Company defines EBITDA margin as EBITDA divided by net sales. The Company considers these non- GAAP measures in evaluating and managing the Company’s operations. The Company believes EBITDA and EBITDA margin are meaningful to investors as they provide useful analyses of ongoing underlying operating trends. -- 30 of 32 -- 31 2022 Q2 Earnings – July 26, 2022. All rights reserved. Certain non-GAAP measures (continued) Description of Special Items - 2021 In addition to reporting financial results in accordance with U.S. GAAP, the Company also provides various non-GAAP measures that incorporate adjustments for the impacts of special items. Special items incorporated in the preparation of these non-GAAP measures for 2021 include the items described below: Net costs for significant litigation: • These relate to 3M's respirator mask/asbestos, PFAS-related other environmental, and Combat Arms Earplugs matters. Net costs include the impacts of changes in accrued liabilities, external legal fees, and insurance recoveries, along with the associated tax impacts. Net costs related to respirator mask/asbestos and Combat Arms Earplugs matters are reflected as special items in the Safety and Industrial business segment while those associated with PFAS-related other environmental matters are primarily reflected as corporate special items in Corporate and Unallocated. -- 31 of 32 -- -- 32 of 32 --